Question-and-Answer SessionSo I thought maybe we'd start with just for you, Jake. If you could remind us of kind of the company's overarching strategy in oncology here. I know you did a little bit of a reboot a couple of years ago and you hosted a session at ASCO, where you kind of talked about this, but maybe just level set us in terms of where you start -- where you stand now in terms of the overall strategy.Jacob Van NaardenExecutive VP & President of Lilly Oncology Yes, I'm happy to do that, and thanks ...